Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New immune cell therapy targets hidden leukemia cells

NCT ID NCT07270978

First seen Dec 24, 2025 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard therapy. The treatment uses the patient's own blood cells that are specially prepared in the lab to better find and attack cancer cells. Participants receive four weekly infusions of these cells, followed by standard chemotherapy. The goal is to check safety and see if the treatment can clear the remaining disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22908, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.